Research map: Consensus statements on the definition, diagnosis, and management of oligoprogressive disease: results of an expert survey of Kazakhstan Cancer Society

Back to the article

Papers in this map

  1. Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial · David A. Palma · 2020 · 1295 citations · Cited by this paper
  2. Emerging roles of haemostatic proteins as markers of disease progression and prognosis in breast cancer · 2026 · Related
  3. Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document · Yolande N. Lievens · 2020 · 679 citations · Cited by this paper
  4. FDA 2025 Cancer Drug Approvals: targeted therapy dominates · 2026 · Related
  5. 6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7) · Fátima Cardoso · 2024 · 232 citations · Cited by this paper
  6. Racial disparities in hepatocellular carcinoma: a TCGA-based gene expression study of Caucasian and Asian populations · 2025 · Related
  7. NRG-BR002: A phase IIR/III trial of standard of care systemic therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical resection (SR) for newly oligometastatic breast cancer (NCT02364557). · Steven J. Chmura · 2022 · 213 citations · Cited by this paper
  8. Metabolic plasticity drives specific mechanisms of chemotherapy and targeted therapy resistance in metastatic colorectal cancer · 2025 · Related
  9. Systematic Evaluation of the Prognostic Impact and Intratumour Heterogeneity of Clear Cell Renal Cell Carcinoma Biomarkers · Sakshi Gulati · 2014 · 173 citations · Cited by this paper
  10. Benign, persistent, and invasive: mechanistic and translational approaches to middle‑ear cholesteatoma · 2026 · Related
  11. Treatment of Oligometastatic Non-Small Cell Lung Cancer: An ASTRO/ESTRO Clinical Practice Guideline · Puneeth Iyengar · 2023 · 128 citations · Cited by this paper
  12. Lorlatinib in advanced ALK-positive NSCLC after prior progression on ALK inhibitors: real-world experience in Russia · 2026 · Related
  13. EGFR-TKIs plus stereotactic body radiation therapy (SBRT) for stage IV Non-small cell lung cancer (NSCLC): A prospective, multicenter, randomized, controlled phase II study · Ping Peng · 2023 · 66 citations · Cited by this paper
  14. Reactive oxygen species (ROS) in cancer: from redox signaling and metabolic plasticity to therapeutic vulnerabilities · 2026 · Related
  15. Stereotactic body radiation therapy in combination with systemic therapy for metastatic renal cell carcinoma: a prospective multicentre study · Natalia Dengina · 2019 · 52 citations · Cited by this paper
  16. Liquid biopsy in breast cancer: current biomarker platforms and clinical applications · 2026 · Related
  17. Canadian Consensus: Oligoprogressive, Pseudoprogressive, and Oligometastatic Non-Small-Cell Lung Cancer · Scott Andrew Laurie · 2019 · 50 citations · Cited by this paper
  18. More than alternative estrogen receptors: the emerging role of GPER-1 and ERα36 in breast cancer · 2026 · Related
  19. Delphi consensus on stereotactic ablative radiotherapy for oligometastatic and oligoprogressive renal cell carcinoma—a European Society for Radiotherapy and Oncology study endorsed by the European Association of Urology · Giulia Marvaso · 2024 · 35 citations · Cited by this paper
  20. CHD4 and NOX4 expression in thyroid tumor tissues · 2026 · Related
  21. Clone Phylogenetics Reveals Metastatic Tumor Migrations, Maps, and Models · Antonia Chroni · 2022 · 11 citations · Cited by this paper
  22. A novel anti-FGFR1 monoclonal antibody OM-RCA-01 exhibits potent antitumor activity and enhances the efficacy of immune checkpoint inhibitors in lung cancer models · Ilya V. Tsimafeyeu · 2024 · 7 citations · Cited by this paper
  23. Stereotactic body radiotherapy for oligometastatic disease: current evidence and future perspectives · Nobuki Imano · 2025 · 4 citations · Cited by this paper
  24. A randomized phase 2 study of the efficacy and safety of stereotactic body radiation therapy (SBRT) in patients with metastatic urothelial carcinoma and oligoprogression on maintenance therapy with avelumab (VOLGA 2). · Ilya V. Tsimafeyeu · 2025 · 2 citations · Cited by this paper
  25. Expert consensus on radiotherapy for oligometastatic esophageal cancer (2025 edition) · Radiation Oncology Physician Branch, Chinese Medical Doctor Association · 2025 · 2 citations · Cited by this paper
  26. Distinct pathways of disease progression with dual checkpoint blockade versus immunotargeted therapy in metastatic renal cell carcinoma · Ilya V. Tsimafeyeu · 2026 · 2 citations · Cited by this paper

Source: OpenAlex (CC0)